Bibliographic record
Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in…
Frías JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M. The Lancet 2023
§1Bibliographic record
§1.1Record
- Authors
- Frías JP, Deenadayalan S, Erichsen L, Knop FK, Lingvay I, Macura S, Mathieu C, Pedersen SD, Davies M
- Title
- Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial
- Source
- The Lancet
- Year
- 2023
- Volume, issue, pages
- 402(10403):720–730
- Digital object identifier
- 10.1016/S0140-6736(23)01163-7
- PubMed identifier
- 37364591
- Record type
- Journal article
- Institute identifier
- CEI-BR-028
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
| Document | Series |
|---|---|
| Monograph: Cagrilintide | Compound monograph |
| Monograph: CagriSema (cagrilintide with semaglutide) | Compound monograph |
| Monograph: Amycretin | Compound monograph |
| Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight… | Evidence synthesis |
| Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes… | Evidence synthesis |
| Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight… | Evidence synthesis |
| Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes… | Evidence synthesis |
| Synthesis: CagriSema (cagrilintide with semaglutide) in obesity and overweight… | Evidence synthesis |
| Synthesis: CagriSema (cagrilintide with semaglutide) in type 2 diabetes… | Evidence synthesis |
| 9 citing documents. | |
§1.3Subject tags
cagrisema t2dm
Compound Evidence Institute · CEI-BR-028 · https://compoundevidence.com/bibliography/frias2023cagri/ · retrieved 30 July 2026